Advertisement

JA Clinical Reports

, 5:3 | Cite as

Rotational thromboelastometry-guided perioperative management of coagulation in a patient with Heyde’s syndrome undergoing transcatheter aortic valve implantation

  • Kumi Fukuhara
  • Takashi Kondo
  • Hirotsugu Miyoshi
  • Hiroshi Hamada
  • Masashi Kawamoto
Open Access
Case report
  • 41 Downloads

Abstract

Background

Changes in coagulability during the hyperacute phase within 24 h after transcatheter aortic valve implantation (TAVI) for Heyde’s syndrome, or aortic stenosis complicated by gastrointestinal angiodysplasia and acquired coagulation dysfunction, have not been clarified. We evaluated perioperative changes in coagulability using rotational thromboelastometry (ROTEM).

Case presentation

A female patient with Heyde’s syndrome in her 80s underwent TAVI. ROTEM showed coagulation dysfunction before and at 6 h after surgery. Improvements in coagulation function started at 12 h after surgery. Based on ROTEM findings, oral administration of antiplatelet agents was started on the day after surgery. No hemorrhagic complications were observed in the postoperative phase.

Conclusions

Evaluation of coagulation function using ROTEM was useful for monitoring perioperative hemostasis and coagulation in this patient.

Keywords

Heyde’s syndrome Rotational thromboelastometry  Transcatheter aortic valve implantation 

Abbreviations

APTT

Activated partial thromboplastin time

AS

Aortic stenosis

AVWS-2A

von Willebrand syndrome type 2A

CFT

Clot formation time

CT

Clotting time

MCF

Maximum clot firmness

PT

Prothrombin time

ROTEM

Rotational thromboelastometry

TAVI

Transcatheter aortic valve implantation

Background

Heyde’s syndrome, or aortic stenosis (AS) complicated by gastrointestinal hemorrhage attributed to gastrointestinal angiodysplasia and acquired coagulation dysfunction, is reported to affect approximately 20% of patients with severe AS [1, 2, 3]. In Heyde’s syndrome, blood flow is accelerated and shear stress is generated when passing through the stenotic aortic valve, which leads to destruction and deficiency of high-molecular-weight vWF multimers. This results in a primary hemostatic disorder classified as acquired von Willebrand syndrome type 2A (AVWS-2A) [3]. Normally, vWF binds to coagulation factor VIII and forms a stable inactive complex. In AVWS-2A, clot formation is impaired by dysfunctional interaction between platelets and the blood coagulation system even with normal factor VIII activity and the absence of abnormalities in PT or APTT [4, 5].

Rotational thromboelastometry (ROTEM; TEM international GmbH, Munich, Germany), a coagulation monitoring method using whole blood at the bedside, can easily evaluate blood coagulation abnormalities that cannot be detected by tests of plasma [6, 7]. In the EXTEM assay, activation of the extrinsic blood coagulation pathway by tissue factor is evaluated. In the INTEM assay, activation of the intrinsic blood coagulation pathway by contact coagulation activators is evaluated. Moreover, in the FIBTEM assay, abnormalities in platelet function and decreased capability for fibrin polymerization caused by impairment of coagulation factors can be differentiated by evaluating the capability for fibrin polymerization when platelet aggregation is inhibited by a platelet aggregation inhibitor and the extrinsic coagulation pathway is stimulated by tissue factor [6, 7, 8].

Although treatment for AS has been shown to ameliorate Heyde’s syndrome [2], no study has evaluated changes in coagulability over time during the hyperacute phase within 24 h after surgery. We describe the perioperative management of a patient with severe AS diagnosed with Heyde’s syndrome undergoing transcatheter aortic valve implantation (TAVI). We used ROTEM to monitor hemostasis and coagulation in order to assess changes in coagulability over time. The timing of postoperative treatment with antiplatelet agents was determined based on ROTEM results.

Case description

A female patient with AS in her 80s had recurrent gastrointestinal hemorrhage, epistaxis, and submucosal hemorrhage during the course of AS. She was 140 cm tall and weighed 45 kg. Transthoracic echocardiography indicated severe AS with an aortic valve area of 0.55 cm2 (trace) and maximum blood flow rate of 6.8 m/s, and mild aortic valve regurgitation. Left ventricular ejection fraction was 65%. No left ventricular wall motion abnormalities were observed. Coronary angiography did not show any significant stenosis. Blood tests indicated anemia (hemoglobin 11.8 g/dL) and thrombocytopenia (platelet count, 8.0 × 104/μL). Prothrombin time (PT) and activated partial thromboplastin time (APTT) were within the normal range, while vWF analysis indicated deficiency of high-molecular-weight multimers (Fig. 1a). Based on these findings, TAVI was scheduled given the patient’s condition. Oral administration of carbazochrome sulfonic acid and tranexamic acid were added prior to surgery, then the bleeding tendency was improved.
Fig. 1

a Results of preoperative analysis of vWF multimers. b Results of postoperative analysis of vWF multimers

General anesthesia was induced with intravenous midazolam (3 mg), fentanyl (100 μg), and rocuronium (50 mg). After tracheal intubation, anesthesia was maintained with propofol (0.5 μg/ml of target control infusion [TCI]) and remifentanil (0.2 μg/kg/min). A prosthetic valve was placed using the transfemoral approach after 4500 units of heparin were administered. Intraoperative respiration and hemodynamics were stable. After placing the prosthetic valve, 45 mg of protamine were administered and the operation was completed. Intraoperative blood loss was 214 ml without apparent bleeding symptoms, then 900 ml of crystalloid and 500 ml of colloid were infused. After the patient recovered from anesthesia, she was transferred to the intensive care unit.

Tables 1 and 2 shows the results of perioperative laboratory and ROTEM findings. ROTEM clearly indicated coagulation dysfunction preoperatively and at 6 h after surgery, which improved starting at 12 h after surgery. Coagulation testing showed that APTT was slightly increased from immediately to 24 h after surgery and normalized on the third postoperative day. Based on ROTEM findings, oral administration of antiplatelet agents was started on the day after surgery. Subsequently, no bleeding tendency was observed clinically. On the day after surgery, vWF analysis showed recovery of high-molecular-weight multimers (Fig. 1b). Transthoracic echocardiography indicated decreased AS (mean aortic valve systolic pressure gradient, 14 mmHg). The patient was discharged in good condition.
Table 1

Blood testing findings

 

Before surgery

6 h after surgery

24 h after surgery

3 days after surgery

Plt (× 103/μL) [150–360]

80

63

61

69

PT-INR [0.85–1.15]

1.02

1.1

1.07

1.05

APTT (s) [26.9–38.1]

32.9

38.8

39.7

35

Fib (mg/dL) [200–400]

225.6

189.5

239.9

319.2

Plt platelet count, PT-INR prothrombin time-international normalized ratio, APTT activated partial thromboplastin time, Fib fibrinogen

Table 2

ROTEM findings

 

Before surgery

6 h after surgery

12 h after surgery

24 h after surgery

3 days after surgery

EXTEM

 CT (s) [38–79]

59

50

54

57

51

 CFT (s) [34–159]

200

130

123

131

103

 A10 (mm) [43–65]

35

44

44

44

49

 MCF (mm) [50–72]

44

52

52

53

56

INTEM

 CT (s) [100–240]

308

403

191

240

157

 CFT (s) [30–110]

190

182

123

127

102

 A10 (mm) [44–66]

38

37

43

44

47

 MCF (mm) [50–72]

47

46

51

51

52

FIBTEM

 A10 (mm) [7–23]

13

14

13

16

 MCF (mm) [9–25]

14

15

14

19

Units are given in parentheses and reference ranges are given in square brackets

ROTEM rotational thromboelastometry, EXTEM tissue factor reagent, INTEM contact coagulation activator reagent, FIBTEM modified EXTEM test with a platelet aggregation inhibitor, CT clotting time, CFT clot formation time, A10 amplitude at 10 min, MCF maximum clot firmness

Discussion

Coagulopathy in Heyde’s syndrome is expected to abate when AS is treated and destruction of high-molecular-weight vWF multimers stops. With both surgical aortic valve replacement and TAVI, recovery of high-molecular-weight vWF multimers has been reported on the day after surgery [2, 9, 10]. Although vWF multimer analysis is used as a standard diagnostic method for AVWS-2A associated with Heyde’s syndrome [11], it is time-consuming and therefore not suitable for chronological evaluation of changes in coagulability during the acute postoperative phase. By measuring PT and APTT, abnormalities in extrinsic and intrinsic coagulation factors are assessed using plasma; neither platelet function, including its interaction with the blood coagulation system, nor the firmness of blood clots can be evaluated [8]. Compared with plasma-based tests, we believe that ROTEM, which monitors the coagulation system using whole blood, can comprehensively and promptly evaluate coagulation dysfunction not reflected by PT or APTT. Thus, we selected ROTEM for perioperative monitoring of hemostasis and coagulation in our patient.

ROTEM clearly indicated coagulation dysfunction preoperatively and at 6 h after surgery, which decreased over time starting at 12 h after surgery in this patient. Although oral antiplatelet agents commonly used for the prevention of embolism after TAVI would be difficult to administer when coagulation dysfunction remains or postoperative gastrointestinal hemorrhage occurs [12], we were able to start oral antiplatelet agents based on improvements in coagulation function on the day after surgery indicated by ROTEM. Consequently, the patient was managed without hemorrhagic complications.

During the preoperative ROTEM evaluation in this patient, decreases in EXTEM-maximum clot firmness (MCF) and INTEM-MCF were observed. FIBTEM-MCF was within the normal range. MCF reflects the maximum firmness of the clot ultimately formed by the interaction between platelets and polymerized fibrin. The ROTEM results for MCF indicated a normal capability for fibrin polymerization and decreased platelet function in our patient. Preoperative increases in EXTEM-clot formation time (CFT), INTEM-CFT, and INTEM-clotting time (CT) in this patient indicate prolongation of the time to clot formation [13], which suggests dysfunction of the coagulation system, specifically the part involving intrinsic and extrinsic coagulation factors. Because PT and APTT measured in blood tests were within the normal range, the above changes were considered to be either the result of abnormalities in blood coagulation pathways other than the coagulation process reflected by PT or APTT or the result of abnormalities in clot formation caused by impaired interaction between platelets and the blood coagulation system associated with AVWS-2A.

Because ROTEM can assess abnormalities in platelet function, its results can serve as a guide to whether platelet transfusion is necessary [13]. As is the case with abnormal platelet function, thrombocytopenia impairs clot formation and thus can affect ROTEM findings [14]. However, improvements in ROTEM findings despite a postoperative decrease in platelet count in our patient suggest that thrombocytopenia was not the main cause of preoperative coagulation dysfunction in this patient. In ROTEM, adhesion of platelets to damaged vascular endothelium mediated by vWF in the physiological environment cannot be reproduced; therefore, direct evaluation of abnormal vWF function is speculated to be difficult [13]. Nevertheless, in this patient, abnormal ROTEM findings were observed despite the absence of clear PT or APTT prolongation after surgery, and postoperative improvement in ROTEM findings over time and recovery of high-molecular-weight multimers of vWF were noted. These findings suggest that both coagulation disorders mediated by abnormal vWF function associated with AVWS-2A and impaired interaction between platelets and the blood coagulation system were occurring before surgery, and that ROTEM findings reflected the overall recovery of coagulability achieved by aortic valve replacement and resulting resolution of Heyde’s syndrome.

We used ROTEM to monitor hemostasis and coagulation in the perioperative management of a patient with Heyde’s syndrome undergoing TAVI and assessed changes in coagulability over time. Based on ROTEM findings indicating improvement, oral antiplatelet agents were started and the patient was managed without hemorrhagic complications. In the treatment of Heyde’s syndrome using TAVI, when coagulation dysfunction not detected by common testing methods continues during the acute postoperative phase, the risk of hemorrhagic complications is increased and the use of oral antiplatelet agents is difficult. For this reason, comprehensive evaluation of coagulability by ROTEM might be a useful method to monitor perioperative hemostasis and coagulation.

Notes

Acknowledgements

Not applicable.

Funding

The authors declare that they have no funding.

Availability of data and materials

The data used in this case report are available from the corresponding author on reasonable request.

Authors’ contributions

KF and TK performed the anesthesia and wrote the main paper. HM, HH, and MK helped to draft the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958;259:196.Google Scholar
  2. 2.
    Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–9.CrossRefGoogle Scholar
  3. 3.
    Loscalzo J. From clinical observation to mechanism—Heyde’s syndrome. N Engl J Med. 2012;367:1954–6.CrossRefGoogle Scholar
  4. 4.
    Seyve L, Richarme C, Polack B, Marlu R. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM). Int J Lab Hematol. 2018;40:84–93.CrossRefGoogle Scholar
  5. 5.
    Kruse-Jarres R. Acquired bleeding disorders in the elderly. Hematology Am Soc Hematol Educ Program. 2015;2015:231–6.CrossRefGoogle Scholar
  6. 6.
    Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008;106:1366–75.CrossRefGoogle Scholar
  7. 7.
    Williams B, McNeil J, Crabbe A, Tanaka KA. Practical use of thromboelastometry in the management of perioperative coagulopathy and bleeding. Transfus Med Rev. 2017;31:11–25.CrossRefGoogle Scholar
  8. 8.
    Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108:1433–46.CrossRefGoogle Scholar
  9. 9.
    Spangenberg T, Budde U, Schewel D, Frerker C, Thielsen T, Kuck KH, Schäfer U. Treatment of acquired von Willebrand syndrome in aortic stenosis with transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2015;8:692–700.CrossRefGoogle Scholar
  10. 10.
    Caspar T, Jesel L, Desprez D, Grunebaum L, Samet H, Trinh A, Petit-Eisenmann H, Kindo M, Ohlmann P, Morel O. Effects of transcutaneous aortic valve implantation on aortic valve disease-related hemostatic disorders involving von Willebrand factor. Can J Cardiol. 2015;31:738–43.CrossRefGoogle Scholar
  11. 11.
    Tiede A. Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res. 2012;130(Suppl 2):S2–6.CrossRefGoogle Scholar
  12. 12.
    Rodés-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, Costa MA, Mega JL, O’Donoghue ML, Ohman EM, Becker RC. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol. 2013;62:2349–59.CrossRefGoogle Scholar
  13. 13.
    Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothoracic Vasc Anesth. 2012;26:1083–93.CrossRefGoogle Scholar
  14. 14.
    Ziegler B, Solomon C, Cadamuro J, Jones N. Thromboelastometric monitoring of the hemostatic effect of platelet concentrates transfusion in thrombocytopenic children undergoing chemotherapy. Clin Appl Thromb Hemost. 2015;21:558–64.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Kumi Fukuhara
    • 1
  • Takashi Kondo
    • 1
  • Hirotsugu Miyoshi
    • 1
  • Hiroshi Hamada
    • 1
  • Masashi Kawamoto
    • 1
  1. 1.Department of Anesthesiology and Critical CareHiroshima University HospitalMinami-kuJapan

Personalised recommendations